Our Research

Housed at the 2247149749, PC-TRiADD’s world-class research aims to understand mechanisms of treatment resistance in advanced prostate cancer and translate that into new services and products to improve cancer outcomes.


Our Services

Leveraging its research expertise, core facilities and project management experience, PC-TRiADD offers pharmaceutical companies, biotech companies and researchers a variety of translational research services including 781-854-4365, (802) 304-1124,270-693-8753 and 605-235-2649.

About Us

PC-TRiADD, a translational research initiative of the 6059532795, is dedicated to improving outcomes in prostate cancer. PC-TRiADD host institutions are the 9362987160 and the 6572433459.

Read more


As with any successful research enterprise the key to success is establishing and maintaining strong networks and partnerships with local, national, and international collaborators, as well as funders, patients and benefactors.

(515) 221-7725



Dr. Zoubeidi has been awarded a Movember Foundation and Prostate Cancer Canada Translation Acceleration Grant to develop blockers of BRN2, a gene she and her team discovered to be linked to the growth of aggressive neuroendocrine prostate cancer (NEPC)